Session Title: Refractive
Session Date/Time: Sunday 17/02/2013 | 08:30-11:00
Paper Time: 09:35
Venue: Hall 3
First Author: : E.Chynn USA
Co Author(s): : M. Plana E. Chynn
Purpose:
To determine whether adult amblyopes (strabismic or refractive) can be safely and effectively treated with advanced surface ablation, and to determine if BCVA, peripheral vision, stereo acuity, and/or subjective functionality can be improved.
Setting:
Park Avenue LASEK, a refractive surgery private practice in New York, USA.
Methods:
A retrospective review was conducted of adult amblyopes at a laser vision correction center who received advanced surface ablation. 13 eyes were identified with the following types of amblyopia: strabismic (15%), anisometropic refractive (38%), or isometropic refractive (46%). Myopic eyes (54%) ranged from spherical equivalence (SE) of -7.50 to -20.75 D (mean –13.70 D), and hyperopic eyes (46%) ranged from SE of +1.00 to +7.50 D (mean +4.54 D). All eyes underwent LASEK or Epi-LASEK with a VISX S4IR excimer laser. Mitomycin C (MMC) 0.01% was given intraoperatively, topical and oral steroids and Vitamin C were given postop, and UV protection mandated to prevent scarring.
Results:
At 1 month postop, UCVA was on average 9.87 lines better than preop UCVA and BCVA was 2.23 lines better than preop BCVA. At the 6 month postop, UCVA was on average 13.67 lines better than preop UCVA, and BCVA was 1.16 lines better than preop BCVA. 14% of myopes and 50% of hyperopes had postop haze; none was clinically significant, as defined by improvement, not loss, of BCVA in all patients. 100% of patients reported functional gain: improved driving (54%), peripheral vision (46%), and sports ability (62%). 100% would undergo the operation again if given the choice.
Conclusions:
Adult patients with refractive and/or strabismic amblyopia may be safely and effectively treated with advanced surface ablation, as evidenced by minimal complications and improvements in UCVA, BCVA and visual function in 100% of eyes. Use of adjunctive therapy to prevent scarring is necessary when treating extreme prescriptions in this category of eyes.
Financial Disclosure:
None
